Lipid-like Gm-Cn Nanoparticles for p53 mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Targeted delivery of therapeutic agents, particularly to cancer cells, remains a challenge, especially for therapies targeting cancer cells with lost or mutated tumor suppressor genes.
Innovation Solution
The use of lipid-like compounds, such as Gm-Cn, to form particles (e.g., nanoparticles) that can deliver cargo, like p53-encoding mRNA, to p53-deficient cancer cells, combined with other therapies like immunotherapy, anti-angiogenesis therapy, or radiotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods are used for therapeutic agents, then the treatment can be administered, but the targeted delivery to cancer cells remains ineffective
Solution Approach 1:
The patent employs lipid-like compounds (Gm-Cn) as complexing agents that form composite nanoparticle structures with therapeutic cargo. These composite particles combine the cargo (mRNA, DNA, or small molecules) with the lipid-like compound to create a delivery vehicle that can target cancer cells effectively while maintaining controlled complexity in the delivery system.
2Reliability
If p53-encoding mRNA is delivered to p53-deficient cancer cells, then tumor suppressor function can be restored, but the delivery to cells with lost or mutated tumor suppressor genes remains challenging
Solution Approach 1:
The patent utilizes the pH-sensitive properties of lipid-like compounds that change their charge state in response to pH variations. The compounds are neutral at physiological pH but become cationic in the acidic endosomal environment, enabling efficient cargo complexation and cellular uptake. This parameter change approach simplifies the delivery process by leveraging natural physiological gradients.
Solution Approach 2:
The lipid-like compounds act as intermediary agents that facilitate the delivery of p53-encoding mRNA to cancer cells. These compounds form transient complexes with the mRNA cargo, protecting it during transit and enabling its release inside target cells, thereby making the delivery process feasible for cells with lost or mutated tumor suppressor genes.
3Reliability
If combination therapies are used to treat cancer, then the therapeutic efficacy can be enhanced, but the complexity of the treatment regimen increases
Solution Approach 1:
The lipid-like compound-based delivery system serves multiple functions: it complexes with various types of cargo (mRNA, DNA, small molecules), targets cancer cells through pH-responsive mechanisms, and can be combined with different therapeutic modalities (immunotherapy, anti-angiogenesis therapy, radiotherapy). This multi-functionality allows the same delivery platform to support combination therapies without proportionally increasing regimen complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective treatment of cancer by restoring tumor suppressor function in targeted cells and enhancing the efficacy of combination therapies.
Implementation Method 1
a core including: p53-encoding mRNA; an ionizable lipid-like compound of Gm-Cn, wherein m≥0 and n≤18, capable of complexing the p53-encoding mRNA
Implementation Method 2
an outer layer including at least one amphiphilic material disposed around the core
Data Source
AI summary
The present disclosure relates to compositions having a lipid-like compound of Gm-Cn, as well as methods of making and using such compositions. Also described herein are methods of treating cancer using such compounds with a combination therapy.